Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0812 in Relapsing-Remitting Multiple Sclerosis
NCT00239655Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing MK0812 with Placebo (2 arms). Primary endpoint: Accrual rate of new GD-enhancing lesions as assessed by MRI at 3 months. Started Aug 2004; status: terminated.
02
Drugs
mk-0812
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00239655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00239655.